QuidelOrtho Corporation reported a total revenue of $2.73 billion for the fiscal year ending December 28, 2025, reflecting a 2% decrease from $2.78 billion in the previous year. This decline was primarily attributed to a significant drop in sales of respiratory products, particularly those related to COVID-19, which accounted for approximately 15% of total revenues, down from 24% in the prior year. The company noted that revenues from its respiratory products fell to $80.2 million in 2025 from $184.9 million in 2024, indicating a substantial reduction in demand as the pandemic's impact waned. In contrast, the Labs business unit saw a 6% increase in revenue, driven by growth in reagents and consumables.
The company undertook a strategic wind-down of its U.S. donor screening portfolio, which contributed to a 54% decline in revenue from that segment. This decision was part of a broader Optimization Plan initiated in 2025, aimed at realigning costs with long-term revenue expectations and improving operational efficiencies. The plan is expected to incur approximately $100 million in pre-tax charges through 2027, with anticipated net cost savings of around $50 million. Additionally, QuidelOrtho announced plans to discontinue the development of its SAVANNA platform, further streamlining its operations.
In terms of operational metrics, QuidelOrtho's employee headcount stood at approximately 6,500 as of the end of 2025, with a significant portion involved in sales and service roles. The company operates across five geographic segments: North America, EMEA, China, JPAC, and Latin America, with North America generating the largest share of revenue at $1.49 billion. The company also reported a goodwill impairment charge of $700.7 million, reflecting a full impairment of goodwill allocated to its EMEA, China, and Latin America reporting units, following a decline in stock price and market capitalization.
Looking ahead, QuidelOrtho anticipates continued fluctuations in demand for its respiratory products and ongoing pricing pressures. The company is focused on enhancing its product offerings and expanding its market share, particularly in high-value profit pools. The management expressed confidence in its ability to navigate the competitive landscape and deliver improved financial results while pursuing strategic opportunities for growth and innovation.
About QuidelOrtho Corp
QuidelOrtho Corporation specializes in developing and manufacturing diagnostic testing solutions across clinical chemistry, immunoassay, molecular diagnostics, point-of-care, and transfusion medicine segments. Its products serve healthcare providers, laboratories, blood banks, and consumers worldwide, supporting disease detection, monitoring, and blood compatibility testing. The company leverages innovative platforms, global manufacturing, and a customer-centric approach to deliver rapid, reliable, and cost-effective diagnostics.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.